Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome
Feng Lin, Thomas E Ichim, Sandeep Pingle, Lawrence D Jones, Shashaanka Ashili, Research and Development, CureScience, San Diego, CA 92121, United States
Santosh Kesari, Cancer Center, John Wayne Cancer Institute and Pacific Neuroscience Institute at Providence Saint John's Health Center, Santa Monica, CA 90404, United States
Author contributions: All authors contributed equally to this paper in conception, literature review and analysis, drafting, critical revision and editing, and approval of the final version.
Conflict-of-interest statement: No conflict of interest to report.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Feng Lin, PhD, Research Scientist, Research and Development, CureScience, No. 10225 Barnes Canyon Road A207, San Diego, CA 92121, United States. email@example.com
Received: July 6, 2020
Peer-review started: July 6, 2020
First decision: July 30, 2020
Revised: August 13, 2020
Accepted: September 14, 2020
Article in press: September 14, 2020
Published online: October 26, 2020